• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

作者信息

Hites Maya, Massonnaud Clément R, Lapique Eva Larranaga, Belhadi Drifa, Jamard Simon, Goehringer François, Danion François, Reignier Jean, de Castro Nathalie, Garot Denis, Lacombe Karine, Tolsma Violaine, Faure Emmanuel, Malvy Denis, Staub Thérèse, Courjon Johan, Cazenave-Roblot France, Dyrhol Riise Anne Ma, Leturnier Paul, Martin-Blondel Guillaume, Roger Claire, Akinosoglou Karolina, Moing Vincent Le, Piroth Lionel, Sellier Pierre, Lescure Xavier, Trøseid Marius, Clevenbergh Philippe, Dalgard Olav, Gallien Sébastien, Gousseff Marie, Loubet Paul, Vardon-Bounes Fanny, Visée Clotilde, Belkhir Leila, Botelho-Nevers Élisabeth, Cabié André, Kotanidou Anastasia, Lanternier Fanny, Rouveix-Nordon Elisabeth, Silva Susana, Thiery Guillaume, Poignard Pascal, Carcelain Guislaine, Diallo Alpha, Mercier Noémie, Terzic Vida, Bouscambert-Duchamp Maude, Gaymard Alexandre, Trabaud Mary-Anne, Destras Grégory, Josset Laurence, Billard Nicolas, Han Thi-Hong-Lien, Guedj Jérémie, Couffin-Cadiergues Sandrine, Dechanet Aline, Delmas Christelle, Esperou Hélène, Fougerou-Leurent Claire, Mestre Soizic Le, Métois Anabelle, Noret Marion, Bally Isabelle, Dergan-Dylon Sebastián, Tubiana Sarah, Kalif Ouifiya, Bergaud Nathalie, Leveau Benjamin, Eustace Joe, Greil Richard, Hajdu Edit, Halanova Monika, Paiva Jose-Artur, Piekarska Anna, Rodriguez Baño Jesus, Tonby Kristian, Trojánek Milan, Tsiodras Sotirios, Unal Serhat, Burdet Charles, Costagliola Dominique, Yazdanpanah Yazdan, Peiffer-Smadja Nathan, Mentré France, Ader Florence

机构信息

Clinic of Infectious Diseases, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.

Université Paris Cité, Inserm, IAME, F-75018 Paris, France; AP-HP, Hôpital Bichat, Département d'Épidémiologie, Biostatistique et Recherche Clinique, F-75018 Paris, France.

出版信息

J Infect. 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16.

DOI:10.1016/j.jinf.2024.106120
PMID:38367705
Abstract
摘要

相似文献

1
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.替沙格韦单抗-西加韦单抗(AZD7442)用于治疗COVID-19住院患者(DisCoVeRy):一项3期、随机、双盲、安慰剂对照试验。
J Infect. 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16.
2
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.半衰期延长的严重急性呼吸综合征冠状病毒 2 中和单克隆抗体 AZD7442(替沙格韦单抗-西加韦单抗)在健康成年人中的安全性、耐受性和药代动力学。
J Infect Dis. 2023 May 12;227(10):1153-1163. doi: 10.1093/infdis/jiad014.
3
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
4
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442(替沙格韦单抗-西加韦单抗)预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
5
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.在TACKLE随机试验中,使用AZD7442(替沙格韦单抗/西加韦单抗)进行门诊治疗可预防6个月内的COVID-19住院,并减少症状进展。
Infect Dis Ther. 2023 Sep;12(9):2269-2287. doi: 10.1007/s40121-023-00861-7. Epub 2023 Sep 26.
6
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.AZD7442(替沙格韦单抗/西加韦单抗)治疗轻至中度新冠肺炎的安全性、有效性和药代动力学:TACKLE试验的15个月最终分析。
Infect Dis Ther. 2024 Mar;13(3):521-533. doi: 10.1007/s40121-024-00931-4. Epub 2024 Feb 25.
7
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析:替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
8
Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.COVID-19 住院成人的被动免疫疗法:六项随机对照试验的个体参与者数据荟萃分析
PLoS Med. 2025 Jul 7;22(7):e1004616. doi: 10.1371/journal.pmed.1004616. eCollection 2025 Jul.
9
Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults.长效新冠病毒中和单克隆抗体组合AZD7442(替沙格韦单抗/西加韦单抗)在健康中国成年人中的安全性、耐受性和药代动力学
Clin Pharmacol Drug Dev. 2025 Aug 13. doi: 10.1002/cpdd.1583.
10
Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.在健康的日本成年人中,半衰期延长的 SARS-CoV-2 中和单克隆抗体 AZD7442(替沙格韦单抗/西加韦单抗)的安全性、耐受性和药代动力学。
J Infect Chemother. 2023 Nov;29(11):1061-1067. doi: 10.1016/j.jiac.2023.07.014. Epub 2023 Jul 29.

引用本文的文献

1
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-omicron or omicron variants: a modelling analysis of the randomized DisCoVeRy trial-authors' response.恩适得对感染前奥密克戎或奥密克戎变异株的COVID-19住院患者的抗病毒作用:随机发现试验的建模分析——作者回应
J Antimicrob Chemother. 2025 Mar 3;80(3):892-893. doi: 10.1093/jac/dkae447.
2
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)对抗病毒单克隆抗体疗法的抗性对中和抗体反应的影响。
Pathog Immun. 2024 Aug 21;9(2):79-93. doi: 10.20411/pai.v9i2.718. eCollection 2024.
3
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.
Evusheld 对感染前奥密克戎或奥密克戎变异株的 COVID-19 住院患者的抗病毒效果:一项随机 DisCoVeRy 试验的建模分析。
J Antimicrob Chemother. 2024 Nov 4;79(11):2887-2895. doi: 10.1093/jac/dkae301.
4
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response.替沙格韦单抗/西加韦单抗用于血液系统疾病患者的新冠病毒暴露前预防——基于SARS-CoV-2疫苗反应的个性化方法
Vaccines (Basel). 2024 Aug 1;12(8):871. doi: 10.3390/vaccines12080871.